Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri(Dana-Farber Cancer Institute), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Martin E. Blackstein(Mount Sinai Hospital), Patrick Schöffski(KU Leuven), Hans Gelderblom(Leiden University Medical Center), Christian Kappeler(Bayer (Germany)), Sebastian Bauer(Science for Life Laboratory), Iris Kuss(Bayer (Germany)), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Peter Hohenberger(University of Mannheim), Peter Reichardt(Helios Hospital Berlin-Buch), Giuseppe Badalamenti(University of Palermo), Dirk Laurent(Menarini Group (Germany)), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Binh Bui Nguyen(Institut Bergonié), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Margaret von Mehren(Temple University Health System), Axel Le Cesne(Institut Gustave Roussy), Heikki Joensuu(Orion Corporation (Finland)), Jianming Xu(Chinese PLA General Hospital), Michael Leahy(The Christie NHS Foundation Trust), Yoon‐Koo Kang(Ulsan College), John Chung(Bayer (United States)), Toshirou Nishida(National Cancer Center)
Cited by 1,400
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k